Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Apellis Pharmaceuticals Inc (APLS)  
$41.70 1.33 (3.29%) as of 4:30 Mon 6/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 114,470,000
Market Cap: 4.77(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $23.65 - $93.31
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,012 624,919 926,129 1,524,597
Total Sell Value $9,608,531 $37,328,501 $54,378,139 $94,079,798
Total People Sold 6 12 14 16
Total Sell Transactions 7 55 79 155
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 717
  Page 2 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Watson David O. General Counsel   •       •      –    2024-02-12 4 S $67.77 $52,926 D/D (781) 103,390 40%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2024-02-12 4 S $67.77 $96,974 D/D (1,431) 93,338 40%     
   Eisele Jeffrey Chief Development Officer   •       •      –    2024-01-30 4 AS $65.53 $63,630 D/D (971) 57,208 -39%     
   Lewis Karen Chief People Officer   •       •      –    2024-01-30 4 AS $65.53 $57,863 D/D (883) 46,387 -39%     
   Francois Cedric Chief Executive Officer   •       •      –    2024-01-29 4 S $64.14 $182,345 D/D (2,843) 317,624 38%     
   Nicholson Nur Chief Technical Officer   •       •      –    2024-01-29 4 S $64.14 $53,555 D/D (835) 67,507 38%     
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2024-01-29 4 S $64.14 $56,057 D/D (874) 1,117,131 38%     
   Eisele Jeffrey Chief Development Officer   •       •      –    2024-01-29 4 AS $64.14 $17,895 D/D (279) 58,179 -38%     
   Watson David O. General Counsel   •       •      –    2024-01-29 4 S $64.14 $58,109 D/D (906) 104,171 38%     
   Lewis Karen Chief People Officer   •       •      –    2024-01-29 4 AS $64.14 $23,539 D/D (367) 47,270 -38%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2024-01-29 4 S $64.14 $58,109 D/D (906) 94,769 38%     
   Delong Mark Jeffrey Chief Business & Strat Officer   •       •      –    2024-01-29 4 S $64.14 $23,539 D/D (367) 65,203 38%     
   Townsend Adam J. Chief Commercial Officer   •       •      –    2024-01-29 4 S $64.14 $58,109 D/D (906) 93,601 38%     
   Eisele Jeffrey Chief Development Officer   •       •      –    2024-01-23 4 AS $63.69 $469,905 D/D (7,378) 58,458 -39%     
   Lewis Karen Chief People Officer   •       •      –    2024-01-23 4 AS $63.69 $272,975 D/D (4,286) 47,637 -39%     
   Francois Cedric Chief Executive Officer   •       •      –    2024-01-22 4 S $65.00 $872,961 D/D (13,431) 320,467 40%     
   Delong Mark Jeffrey Chief Business & Strat Officer   •       •      –    2024-01-22 4 S $65.00 $89,954 D/D (1,384) 65,570 40%     
   Watson David O. General Counsel   •       •      –    2024-01-22 4 S $65.00 $271,943 D/D (4,184) 105,077 40%     
   Eisele Jeffrey Chief Development Officer   •       •      –    2024-01-22 4 S $65.00 $104,449 D/D (1,607) 65,836 40%     
   Nicholson Nur Chief Technical Officer   •       •      –    2024-01-22 4 S $65.00 $168,535 D/D (2,593) 68,342 40%     
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2024-01-22 4 S $65.00 $230,801 D/D (3,551) 95,675 40%     
   Chopas James George VP/Chief Accounting Officer   •       •      –    2024-01-22 4 S $65.00 $68,961 D/D (1,061) 39,067 40%     
   Townsend Adam J. Chief Commercial Officer   •       •      –    2024-01-22 4 S $65.00 $221,831 D/D (3,413) 94,507 40%     
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2024-01-22 4 S $65.00 $254,329 D/D (3,913) 1,118,005 40%     
   Lewis Karen Chief People Officer   •       •      –    2024-01-22 4 S $65.00 $112,963 D/D (1,738) 51,923 40%     
  717 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us